Aclacinomycin A (Synonyms: Aclarubicin)

Name: Aclacinomycin A
Brand: MedChemExpress
SKU: HY-N2306
Rating: 5.0 (3 reviews)

Cat. No.: HY-N2306 Purity: 98.94%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Aclacinomycin A (Aclarubicin) is an orally active and potent anthracycline antitumor antibiotic. Aclacinomycin A is an inhibitor of topoisomerase I and II. Aclacinomycin A inhibits synthesis of nucleic acid, especially RNA. Aclacinomycin A might inhibit the 26S protease complex as well as the ubiquitin-ATP-dependent proteolysis.

For research use only. We do not sell to patients.

Aclacinomycin A Chemical Structure

CAS No. : 57576-44-0

Size	Price	Stock	Quantity
1 mg	USD 195	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 480	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 850	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Aclacinomycin A:

Aclacinomycin A hydrochloride In-stock
Aclacinomycin A (Standard) Get quote

3 Publications Citing Use of MCE Aclacinomycin A

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Topoisomerase Isoform Specific Products:

View All Isoforms

Topoisomerase Topo I Topo II

View All Antibiotic Isoform Specific Products:

View All Isoforms

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Topoisomerase I

Topoisomerase II

Cellular Effect

Cell Line	Type	Value	Description	References
DU-145	IC₅₀	0.129 μM Compound: 12	Cytotoxicity in human DU-145 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay Cytotoxicity in human DU-145 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay	[PMID: 33064004]
HCT-116	IC₅₀	0.04 μM Compound: 12	Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay	[PMID: 33064004]
K562	IC₅₀	0.076 μM Compound: 12	Cytotoxicity in human K562 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay Cytotoxicity in human K562 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay	[PMID: 33064004]
MEL-JUSO	IC₅₀	0.048 μM Compound: 12	Cytotoxicity in human MEL-JUSO cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay Cytotoxicity in human MEL-JUSO cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay	[PMID: 33064004]
PC-3	IC₅₀	0.101 μM Compound: 12	Cytotoxicity in human PC-3 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay Cytotoxicity in human PC-3 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay	[PMID: 33064004]
U-87MG ATCC	IC₅₀	0.137 μM Compound: 12	Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay	[PMID: 33064004]

In Vitro

Aclacinomycin A (0-120 μM, 30 min) inhibits the ubiquitin-ATP-dependent proteolytic activity of rabbit reticulocytes in a dose-dependent manner, with an IC₅₀ of 52 μM. But it does not inhibit the ubiquitination^[1].
Aclacinomycin A inhibits ubiquitin-ATP-dependent proteolysis after the conjugation of ubiquitin to proteins^[1].
Aclacinomycin A (0-2.4 μM, 3 h) inhibits the topo II catalytic activity^[2].
Aclacinomycin A (0-1.8 μM, 3 h) has negative effect on the proliferative rate of V79 and irs-2 cells^[2].
Aclacinomycin A emits fluorescence and that human-cervical cancer HeLa cells exposed to Aclacinomycin A exhibits bright fluorescence signals in the cytoplasm when fluorescence microscopy was performed using the red filter (excitation 530-550 nm/emission 575 nm)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	V79 and irs-2 cells
Concentration:	0, 0.006, 0.12, 1.2, and 2.4 μM
Incubation Time:	3 h
Result:	Inhibited the topo II catalytic activity in a dose-dependent manner. The loss of topo II catalytic activity in ACLA-treated cells was in all cases significant compared with non-treated cells.

Cell Proliferation Assay^[2]

Cell Line:	V79 and irs-2 cells
Concentration:	0, 0.12, 0.25, 0.37, 0.6, 1.2, 1.8 μM
Incubation Time:	3 h
Result:	Showed a dose-dependent negative effect on the proliferative rate of V79 and irs-2 cells, but the reduction in surviving colonies was higher in the radiosensitive irs-2 cells for most of the ACLA doses tested.

In Vivo

Aclacinomycin A (0.75-6 mg/kg, IP, daily) dose-dependently exhibits tumor growth in mice-based Leukemia P-388 model^[4].
Aclacinomycin A (0.6-20 mg/kg, Orally, daily) exhibits an antitumor effect on leukemia L-1210^[4].
Aclacinomycin A is very well absorbed in mice, rats, and dogs after its oral administration. The oral LD₅₀ (76.5 mg/kg) is about twice the iv LD₅₀ (35.6 mg/kg) in mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	DBA/2, CDF₁ (BALB/c×DBA/2) mice with Leukemia P-388 (90-110 g)^[4].
Dosage:	0.75 mg/kg, 1.5 mg/kg, 3 mg/kg, 6 mg/kg
Administration:	Intraperitoneal administration daily for 10 days starting 3 hr after transplantation.
Result:	Inhibited tumor growth.

Animal Model:	CDF₁ mouse with Leukemia L-1210^[4]
Dosage:	0.6 mg/kg, 1.25 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg
Administration:	Orally, daily for days 1-9
Result:	Exhibited an antitumor effect on leukemia L-1210.

Clinical Trial

Molecular Weight

811.87

Formula

C₄₂H₅₃NO₁₅

CAS No.

57576-44-0

Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C([C@@H]1C2=CC(C(C3=CC=CC(O)=C43)=O)=C(C4=O)C(O)=C2[C@@H](O[C@@](O[C@@H](C)[C@H]5O[C@@](O[C@@H](C)[C@H]6O[C@](CCC7=O)([H])O[C@H]7C)([H])C[C@@H]6O)([H])C[C@@H]5N(C)C)C[C@]1(O)CC)OC

Initial Source

Streptomyces sp.

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (61.59 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.2317 mL	6.1586 mL	12.3172 mL
5 mM	0.2463 mL	1.2317 mL	2.4634 mL
10 mM	0.1232 mL	0.6159 mL	1.2317 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 99.30%

Select Batch:

Data Sheet (285 KB) SDS (479 KB)

COA (231 KB)

Handling Instructions (2659 KB)

References

[1]. Isoe T, et al. Inhibition of different steps of the ubiquitin system by CDDP and aclarubicin. Biochim Biophys Acta. 1992 Sep 15;1117(2):131-5. [Content Brief]

[2]. Hajji N, et al. Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor. Mutat Res. 2005 May 2;583(1):26-35. [Content Brief]

[3]. Iihoshi H, et al. Aclarubicin, an anthracycline anti-cancer drug, fluorescently contrasts mitochondria and reduces the oxygen consumption rate in living human cells. Toxicol Lett. 2017 Aug 5;277:109-114. [Content Brief]

[4]. Hori S, Shirai M, Hirano S, Oki T, Inui T, Tsukagoshi S, Ishizuka M, Takeuchi T, Umezawa H. Antitumor activity of new anthracycline antibiotics, aclacinomycin-A and its analogs, and their toxicity. Gan. 1977 Oct;68(5):685-90. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.2317 mL	6.1586 mL	12.3172 mL	30.7931 mL
	5 mM	0.2463 mL	1.2317 mL	2.4634 mL	6.1586 mL
	10 mM	0.1232 mL	0.6159 mL	1.2317 mL	3.0793 mL
	15 mM	0.0821 mL	0.4106 mL	0.8211 mL	2.0529 mL
	20 mM	0.0616 mL	0.3079 mL	0.6159 mL	1.5397 mL
	25 mM	0.0493 mL	0.2463 mL	0.4927 mL	1.2317 mL
	30 mM	0.0411 mL	0.2053 mL	0.4106 mL	1.0264 mL
	40 mM	0.0308 mL	0.1540 mL	0.3079 mL	0.7698 mL
	50 mM	0.0246 mL	0.1232 mL	0.2463 mL	0.6159 mL
	60 mM	0.0205 mL	0.1026 mL	0.2053 mL	0.5132 mL

Aclacinomycin A Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Aclacinomycin A (Synonyms: Aclarubicin)

Customer Review

Other Forms of Aclacinomycin A:

Aclacinomycin A Related Antibodies

3 Publications Citing Use of MCE Aclacinomycin A

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Topoisomerase Isoform Specific Products:

View All Antibiotic Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Aclacinomycin A Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Aclacinomycin A Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report